Orlistat and Phentermine

Orlistat

If a patient does not manage to significantly reduce his weight by means of exercise and diet, pharmacotherapy is used.

Drugs for obesity treatment are prescribed to patients with a BMI more than 30 kg / m2. Anti-obesity drugs can also be prescribed to patients with a BMI of 27 kg / m2 in the presence of such risk factors as hypertension, atherosclerosis, and dyslipidemia.

At present, pharmacological agents are used to treat obesity:

Centrally acting drugs – Phentermine (Adipex, Lomaira, Suprenza)

Peripherally acting drugs – Orlistat (Alli, Xenical).

One of the modern options of obesity therapy in adults and adolescents over 18 years old is use of Phentermine. The drug has an anorexigenic effect and it is considered one of the drugs of choice for treatment of patients with increased appetite and tendencies for overeating.

The vast majority of obesity cases are associated with overeating and inability to control excessive appetite.

Anorectic Phentermine inhibits reuptake of neurotransmitters serotonin and norepinephrine, and to a lesser extent, dopamine. This leads to decrease in appetite and rapid onset of a feeling of satiety even when consuming small portions of food.

Orlistat effect is aimed at reducing fat absorption in the intestine. Fats are the main factor of nutrition that contribute to accumulation of excess weight. Therefore, correcting the body weight, their consumption should be reduced.

By suppressing activity of enzyme of the pancreas – lipase, about 30% of fats entered the body from food are not digested and are excreted in feces.

The issue of drug therapy of obesity should be considered only in conjunction with an appropriate diet and increase in physical activity.